Navigation Links
Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
Date:6/6/2008

Sangamo Announces Completion of Accrual and Expansion Plans for SB-509-701

Phase 2 Clinical Trial for Treatment of Moderate to Severe Diabetic

Neuropathy

SAN FRANCISCO, June 6 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the completion of patient enrollment into its Phase 2 clinical trial (SB-509-701) in subjects with moderate to severe diabetic neuropathy. Additionally, based upon positive initial data, the company plans to expand this study and enroll additional subjects to obtain more information for the design of a potential Phase 3 trial.

"Our initial review of data from SB-509-701, while preliminary, was quite encouraging," stated Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "As such, we plan to double the number of subjects in this study and evaluate an additional treatment schedule. Because of the definitive nature of the endpoint in this trial -- recovery of nerve conduction velocity or NCV -- these additional data may provide important information which could potentially expedite a Phase 3 study."

SB-509-701 is a randomized, single-blind, placebo-controlled, repeat-dosing, multi-center Phase 2 clinical trial of SB-509 in subjects with moderate to severe diabetic peripheral sensory motor neuropathy (DN). The study is designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetic subjects that have unmeasurable nerve conduction velocity (NCV) in at least one of the nerves in the leg.

In the initial trial, 45 subjects have completed enrollment. Subjects were randomized to one of two groups in a 2:1 ratio. The larger group (approximate
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
2. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
5. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
6. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
7. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
8. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
11. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
(Date:12/24/2014)... ResMed (NYSE: RMD ) today announced ... medical device manufacturer BMC Medical Co., Ltd. ... listed below infringe ResMed,s patents, and entered an order prohibiting ... the United States : , iVolve ... Willow nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... , MELBOURNE, Australia, Sept. 3 Cytopia Limited,s ... passed US Food and Drug Administration (FDA) review. CYT387 is ... haematological disorders. The company,s IND application is now active and ... in the United States. , , CYT387 ...
... Hedgehog trial results suggest antitumor activity in basal cell skin cancer ... A study published today in the New England Journal of ... metastatic basal cell skin cancer tested at the Virginia G. Piper ... tumor shrinkage and limited side effects in patients. , , ...
Cached Medicine Technology:Cytopia's CYT387 Receives FDA Clearance to Start US Clinical Trials 2Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 2Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 3Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4
(Date:12/26/2014)... “Many people become overwhelmed by the thought ... and phone calls with insurance companies,” The Jones Firm ... free eBook on pedestrian and bicycle accidents . ... bicycle auto accident claims assures the injured individual that ... handling their case while they focus on recovering. ...
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... 2014 Recently, iFitDress.com, the popular online supplier ... announced its new selection of black one-shoulder cocktail dresses ... now; they are available at discounted prices, up to 70% ... will last for three weeks only. You know, we have ... are interested in our new items can visit our website ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 BambooFlooringChina.com sells ... high quality bamboo flooring. Today, the company announces ... in many styles and colors. , BambooFlooringChina.com is the ... CEO, the promotion is valid until Jan. 20, 2015. ... strips and woven with a natural thread. All the ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... , , , ... a hospitalist management company, presented performance improvement and cost savings ... Services during the recent American Hospital Association (AHA) Leadership Summit. ... President, Medical Affairs at Reid, presented average three-month-trend results of ...
... TAMPA, Fla., Aug. 6 Gold Standard/Elsevier ... launch of three MedCounselor consumer drug information modules for pharmacies ... how to take medications safely, assists in identifying unknown tablets ... are indispensable in helping to increase consumer compliance to their ...
... , NEW YORK, Aug. 6 ... shown to significantly help improve the appearance of unwanted discoloration, age ... select physicians to help their patients achieve picture perfect skin. A ... in leading physician offices for $120 per 1 ounce pump. , ...
... solid year-to-date performance and, positive outlook for the remainder ... SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: SXCI ... periods ended June 30, 2009. Financial references are in U.S. dollars unless ... ------------------, - Revenue was ...
... , , , ... Aug. 6 Stereotaxis, Inc. (Nasdaq: STXS ) today reported ... Revenue for the recent second quarter totaled $12.6 million, an increase of ... During the quarter, the Company recognized revenue on eight Niobe(R) Magnetic ...
... ... insurance costs is essential if we expect to create jobs and rebuild the economy says ... Los ... as insurance costs run amok and further sideline a failing economy, according to President Obama. ...
Cached Medicine News:Health News:Inpatient Management, Inc. and Reid Hospital Achieve Performance Improvement and Cost Savings 2Health News:Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules 2Health News:Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules 3Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 3Health News:SXC Health solutions announces record second quarter financial results 2Health News:SXC Health solutions announces record second quarter financial results 3Health News:SXC Health solutions announces record second quarter financial results 4Health News:SXC Health solutions announces record second quarter financial results 5Health News:SXC Health solutions announces record second quarter financial results 6Health News:SXC Health solutions announces record second quarter financial results 7Health News:SXC Health solutions announces record second quarter financial results 8Health News:SXC Health solutions announces record second quarter financial results 9Health News:SXC Health solutions announces record second quarter financial results 10Health News:SXC Health solutions announces record second quarter financial results 11Health News:SXC Health solutions announces record second quarter financial results 12Health News:SXC Health solutions announces record second quarter financial results 13Health News:SXC Health solutions announces record second quarter financial results 14Health News:SXC Health solutions announces record second quarter financial results 15Health News:SXC Health solutions announces record second quarter financial results 16Health News:SXC Health solutions announces record second quarter financial results 17Health News:SXC Health solutions announces record second quarter financial results 18Health News:SXC Health solutions announces record second quarter financial results 19Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 2Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 3Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 4Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 5Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 6Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 7Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 8Health News:Sinking Economy Hit Hard by Soaring Healthcare Costs, Says MedicareSupplementPlans.com 2
... designed for patient comfort as well as dependable ... at 5cm intervals and line marked each centimeter., ... available spanning most clinical needs and the range ... or two sensors., ,Flexilog single-use catheters are ...
... UES catheter is made of two probes ... choice of sensor distance., ,VersaFlex disposable ... ,Alpine's VersaFlex catheters are the smallest ... French), and are the perfect combination of ...
... Slimline single-use pH catheters are ... cross-contamination and allow greater patient comfort ... ,Medtronic pH measurement systems have been ... that allow an accurate room-temperature calibration. ...
FLEXILOG spare part....
Medicine Products: